Abstract | Recent research has raised hopes for impressively accurate screening for cancer with molecular biomarkers. These molecular markers will probably be more sensitive and specific than older screening modalities, as well as easier to use. In this Essay, I argue that these sensitive screening tests might be clinically valuable -but that they will present unique issues in implementation and interpretation. These issues are likely to affect the way clinicians conduct screening and the way that they make diagnoses in individuals who screen positive for cancer.
Newer proteomic and genetic technologies have invigorated research into cancer screening, but the use of molecular biomarkers for the early detection of cancer is not new. Testing stools for haem and measuring levels of serum prostate-specific antigen (PSA) are established screening modalities for bowel and prostate cancer, respectively, with each method relying on the detection of particular molecular entities. Carcinoembryonic antigen (CEA) and cancer antigen 125 (CA-125) are other familiar molecular biomarkers that were found to be ineffective for screening, but that are currently used for follow-up assessments in patients with colorectal and ovarian cancer, respectively [1] [2] [3] . In developed countries, the general public has high expectations for cancer screening that seemingly extend beyond the evidence for its efficacy 4, 5 . Potentially, screening with molecular biomarkers could help to meet these expectations, but recent reports of striking accuracy for some molecular screens 6, 7 have not been confirmed 8, 9 .
Nonetheless, there is considerable on-going research, and new molecular cancer markers for several cancers are likely to reach the clinic 10 . This Essay considers the uses and the interpretation of molecular biomarkers for detecting cancer as part of a screening process -taking advantage of the knowledge gained from more traditional screening tests and the experience to date with familiar molecular markers, such as PSA and stool haem testing.
Molecular and anatomical screening
Many established screening tests are explicitly designed to detect tumour masses, and in this sense they are 'anatomical' . This is clearly the case for almost all radiographic screening (mammography and chest X-rays, for example), physical examination (such as, breast and pelvic examinations) and endoscopy. Because some benign masses can look like cancer, there are false-positive anatomical screens. For example, lung cancer screening with computed tomography detects small nodules that are often benign remnants of infections or of inflammatory processes, but that need to be followed-up to clarify whether they are actually malignant or benign 11 . Other common screening tests (such as cervical Papanicolaou (PAP) smears) are anatomical in the sense that they assess the microscopic anatomy of whole cells.
Conversely, molecular biomarkers are independent of the presence of a detectable tumour mass or even of the detection of intact transformed cells. Instead, they represent detection at a distance, using molecular signals in the blood or excretia to indicate the presence of a cancer or a preinvasive lesion. These molecular biomarkers fall into four groups (TABLE 1) . Some are products of the neoplastic process that are shed by the tumours, such as mutated or hypermethylated DNA ('carcinogenesis markers'). Others are molecular species that are generated by the host in response to the cancer ('response biomarkers'); examples include antibodies, protein degradation products 12 and acute-phase reactants 13 . A third group of biomarkers, including blood in stools or PSA in serum, are released in abnormal amounts as a result of anatomical or metabolic disruption associated with a tumour ('released biomarkers'). The final group of molecular markers comprises factors associated with or supporting the underlying carcinogenesis ('risk biomarkers'); examples include high oestradiol levels in relation to breast cancer, markers of human papilloma virus in relation to cervical cancer and incompletely penetrant genetic risk factors.
These classes of biomarkers will probably behave differently in early detection. Carcinogenesis markers are likely to be fairly specific for invasive or pre-invasive neoplasia, as they are essentially found only in on-going carcinogenesis. Testing for PSA levels or for the presence of blood in stools has already shown that released biomarkers can be nonspecific: pathology other than cancer often leads to their release into blood and stools, respectively. Risk biomarkers are often abnormal in individuals without cancer, so these biomarkers should really be considered to be risk factors -markers of cancer risk rather than markers of cancer. Typically, only a minority of individuals with the risk factors actually develop the associated disease.
Thus, just as benign masses can mimic tumours or can obscure tumours in anatomical screening, pathological and metabolic processes will also affect the specificity of molecular screening, especially if it is not based on carcinogenesis markers. PSA provides many examples: haemodilution of PSA levels in obese men 14, 15 , distortion of PSA by medication 14 and increases in PSA levels owing to prostatitis 16 . Inflammation -a risk factor for cancer in many organs -might be a particular problem, as it shares molecular mediators with carcinogenesis 17, 18 . The validation of molecular tests, including controls with various benign inflammatory and acute conditions, will help to avoid these potential problems. However, problems may become recognized only as the screen is widely used outside the often narrow populations that are tested in validation research. Consequently, Phase IV post-approval studies may be needed to fully understand some molecular-based screening tests. These studies will enable us to define the metabolic limitations of such a screening test, as radiologists have learned to deal with anatomical factors that impede a clear assessment of visualized masses.
Advantages of molecular screens
In formal terms, screening is "the examination of asymptomatic people in order to classify them as likely or unlikely to have the disease that is the object of screening. " (REF. 19 ). In a subsequent, diagnostic step, individuals who screen positive are then further assessed to see whether they have the target disorder. A molecular screen in itself cannot diagnose cancer. Diagnosis requires anatomical evidence: confirmation and histological characterization of the cancer and the localization of the tumour in the involved organ. Successful molecular screens will serve as high-quality triage, separating patients who can forgo anatomical assessment from those who are more likely to harbour a tumour and so need further anatomical investigation.
As the development of early detection biomarkers progresses, it is natural that the accuracy of molecular screening should be the focus of discussion, but these screening tests will probably bring advantages that are independent of their accuracy. One advantage is that the tests are convenient and safe -typically requiring only the donation of blood, urine or stools. Measuring these molecular biomarkers does not involve tests that deliver radiation, a visit to the clinic or unpleasant procedures, as is needed for colonoscopy. Thus, the use of molecular biomarkers is likely to improve the uptake of screening by the general population and make repeated testing practical and affordable. This would increase the sensitivity of the screening process, and would correspondingly increase the chances of detecting early cancers. However, it would also increase the potential for false positives, with the adverse downstream consequence of unnecessary diagnostic follow-ups.
Another advantage of molecular biomarkers is that they can be easily combined into panels using mathematical techniques such as logistical models or recursive partitioning to enhance sensitivity and specificity. Such combinations might be less susceptible to measurement artefacts than the individual markers. Also, the quantitative nature of many molecular markers means that they can potentially be personalized; using age-, sex-and race-specific norms, for example 20 . Sensitivity: the 'yin/yang' of screening It is expected that newly developed molecular screens will be more sensitive and specific than existing molecular screens. High specificity will bring clear benefits and has no downside: false-positive screening results will be minimized. However, sensitivity is another story. Although the ability to detect early cancers, perhaps even before there is much of a tumour mass present, is a defining characteristic of early cancer diagnosis with molecular biomarkers, it is also central to some potential problems.
Overdiagnosis. As molecular screening followed by early diagnosis becomes more sensitive, it will find malignancies that -even if untreated -would progress to clinically relevant cancers only slowly and perhaps not at all during a patient's natural lifespan [21] [22] [23] . PSA screening for prostate cancer is a well-known example. In the Prostate Prevention Trial, 24% of biopsies were positive for prostate cancer in men randomized to placebo 24 , a far higher proportion than would have been diagnosed with clinical cancer during their remaining lifetimes. The overdiagnosis associated with PSA screening led to a dramatic increase in the recorded incidence of prostate cancer in the United States 25 . Most of the 'extra' cases would not have had any clinical consequences even if they had not been discovered and treated. Thyroid and breast tissue also frequently contain nests of what are likely to be 'pseudocancer' that could be detected with sufficiently sensitive screening. Although the magnitude of overdiagnosis in breast cancer is controversial, the high estimates are above 50% for tumours detected by mammography 29 . For any cancer with a subclinical reservoir of cases, one can anticipate an increase in the observed incidence of that cancer after the institution of molecular screening, with cases made up of both clinically relevant tumours and tumours that would never harm the patient if left untreated. As molecular cancer screening becomes more widely used, the need to separate truly aggressive lesions from those that are unlikely to be clinically troublesome will correspondingly grow.
Detected cancers that cannot be found. A novel problem of molecular screening could well be the detection of minute invasive cancers that cannot be found using anatomical techniques, such as endoscopy and radiography
. Clinically, a patient with such a lesion would appear to have a false-positive molecular screen. Methylated gene markers for prostate cancer 30 have clearly illustrated this point. Cancers that cannot be located could be a serious issue for patients with a positive molecular screen for neoplasia in the bronchial tree, in Barrett's oesophagus or in ulcerative colitis, where discrete lesions are often not evident on anatomical imaging. This problem is rare after an anatomical screen, as these screens locate a tumour mass that can be biopsied to ascertain the diagnosis.
The definitive treatment of most epithelial cancers is surgical removal. But it is impossible to treat a cancer surgically if it cannot be located. This need to locate lesions that have been 'detected' by screening means that the full potential of molecular screening might not be realized until it is coupled with enhanced imaging techniques, such as fluorescence endoscopy and positron emission tomography scanning [31] [32] [33] [34] . However, 'mini-cancers' detected in this way may behave differently from their more familiar counterparts that are detected through current screening means. It is possible that some of these mini-cancers may not be clinically important, even in organ sites that are not currently recognized as having a reservoir of asymptomatic cases.
A related problem may arise because different cancers share molecular features, creating cross-reactivity in carcinogenesis or in response biomarkers. This was an issue for CEA, as it is expressed in several gastrointestinal cancers 35 . Individual newer molecular markers may suffer from the same problem. Methylated APC in serum has been found in patients with lung cancer 36 , as well as in some patients with oesophageal cancer 37 . Mutated KRAS may be found in serum from patients with diverse cancer types 38 . Methylated RAS association domain family protein 2 (RASSF2) and secreted frizzled-related protein 2 (SFRP2) have been seen in stool samples from patients with either stomach or colorectal cancer 39 . As long as the positivity is limited to a few cancer sites, the follow-up of a screen-positive subject might be straightforward, but it will probably not be helpful to have a screen that is positive for cancer 'somewhere' . It should be possible to address this issue with multi-marker panels and careful validation of the early detection markers. Ideally, validation would include checking results in patients with other malignancies.
Other implications of molecular screening Pre-malignant lesions. As the molecular defects of early cancer are often similar to those of intraepithelial neoplasia 40 , molecular screening for cancers will probably identify substantial numbers of pre-invasive lesions. In organs such as the colorectum and cervix, these can be removed fairly easily to reduce the risk of future cancer. Excision of pre-invasive lesions identified in less accessible tissues, such as the pancreas, entails considerable morbidity. It may not be clear what should be done to address the increased risk of invasive cancer, particularly as the natural history of these screen-detected lesions may not be well characterized. Increased surveillance would presumably be recommended and conceivably chemoprevention -but this has not been shown to be effective outside the colorectum and breast 41, 42 . Such clinical dilemmas need to be considered before the introduction of molecular screens that might detect early disease for which there is no effective treatment.
Persistent markers. After a tumour has been resected, carcinogenesis biomakers and release biomarkers would presumably revert to normal, and so signal successful treatment. However, some risk biomarkers and some reaction biomarkers (such as antibodies) might remain in the abnormal range even after the responsible lesions are completely removed. For example, long-term hormonal patterns that promoted carcinogenesis would presumably continue, and some antibodies generated by a tumour may persist. Markers that do revert to normal after successful treatment could be used to follow disease recurrence Box 1 | Cancer that cannot be found and progression, in the way that PSA (for prostate cancer), CEA (for colorectal cancer) and CA-125 (for ovarian cancer) are currently used. Again, advanced anatomical detection may aid the molecular screen to locate recurrent neoplasia that is not otherwise evident. Ideally, the validation of molecular screening markers would include the study of their behaviour as markers of disease progression after the excision of the tumours that are detected.
Conclusions
Because of its independence from tumour masses, screening for cancer with molecular biomarkers has different properties from those of anatomical screening. These screening tests are convenient and cheap in comparison to anatomical modalities, and more user-friendly. We can hope that new molecular screens will be more accurate than older screens. However, the sensitivity of the screens has predictable implications, inevitably shifting our recognition of cancer towards the less severe end of the carcinogenesis range. In some organs, it may even be a challenge to find the cancers that are indicated by the molecular biomarkers. In any case, improved anatomical imaging will probably be needed to take full advantage of the more sensitive detection.
The consequences of the shift to the detection of very early cancers have been suggested by our experience with older molecular biomarkers, such as PSA. Some of the cancers detected might not need to be treated, and being able to identify this subset will be an important issue for the clinical application of molecular screening. More generally, studies to document the cost-effectiveness of the screening will be needed, as will research into the proper treatment of any early lesions found. As for any new screening modality, the benefits of molecular screening will need to be weighed against its potential limitations.
